Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
HOME > TRENDS
TRENDS
- Japan’s 1st DPP-4/SGLT-2 Pair to Hit Shelves Shortly, Will Shift to Combo Drugs Gain Ground?
September 5, 2017
- Japan Generic Market Decelerating, 3 Majors Log Only Slight Uptick in April-June
August 22, 2017
- Pharmas’ Rep Number Corrections in Full Force amid Bleak Market Outlook, Silver Lining Seen in “Specialty” Arena
August 18, 2017
- Top Drugs Jostling for Higher Share amid Tepid Market, Trulicity Overtakes Victoza in GLP Space: April-June
August 7, 2017
- Japan Sales of Global Pharmas Dipped in 2016? Price Cuts, Sluggish LLPs Weighs: Jiho Tally
June 28, 2017
- Authorized Generics Solidifying Their Presence in Japan Gx Market
June 16, 2017
- Japan Pharma Earnings Show SGLT-2 Market Uptake Still Slow
May 22, 2017
- Astellas’ LLP Sale to Private Equity Group Signals New Business Model for Older Drugs
April 10, 2017
- Mitsubishi Tanabe’s Exit Shows Research-Driven Makers’ Generic Biz at Crossroads
March 31, 2017
- As Takeda’s R&D Rejig Progresses, Biotech JV Launch Sets Direction for Its Japan Regime
March 23, 2017
- Daiichi Sankyo Espha Goes on AG Spree as It Wins Nod for 7 Major Brands
February 16, 2017
- Montelukast AG Achieves Rapid Market Penetration, Enjoys Stronger Start than Candesartan AG
February 7, 2017
- AGs Set to Break into 10 Billion Yen Territory in Japan
November 14, 2016
- Gilead Stays Pat on Hep C Plan, Japan Chief Says Innovation Outstrips Re-Pricing Hit
October 18, 2016
- Japan’s Established Drug Market Shines as Renewed Opportunity for Foreign Generic Firms
September 26, 2016
- Sumitomo Dainippon Feeling Sense of Crisis about Operating Profit to Approach Zero; Will Offer Early Retirement and Cut Executive Compensation
September 15, 2016
- Surprise Rule Change Pops Up Yet Again, This Time with Taltz
September 5, 2016
- Top Global Pharmas Lackluster in Japan while Hep C Drug Makers Flourish
June 21, 2016
- Success of Daiichi Sankyo’s New Midterm Plan to Hinge on Edoxaban; 120 Billion Yen Sales Target Set for FY2020
April 13, 2016
- Multiple Authorized Generics Get Approval towards June Listing as Pharmas See Opportunities
February 17, 2016
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…